We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.
- Recent FATE Stock Price: $4.24
- Yearly Gain for FATE stock: -91.22%
- Market Cap for FATE stock: $412.00M
- P/E Ratio for FATE stock: -3.61
Will FATE's stock price go up? Is there an accurate FATE stock forecast available?
TipRanks.com reports that Fate Therapeutics currently has 20 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $21.46. The target pricing ranges from a high FATE forecast of $115.00 down to a low forecast of $4.00. Fate Therapeutics (FATE)’s last closing stock price was $4.24 which would put the average price target at 406.13% upside.
In addition, TradingView issued a Strong Sell rating for FATE stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on FATE stock.
Other analysts covering FATE include:
- Mara Goldstein of Mizuho Securities issued a Buy rating with the price target of $ 12 on 1 day ago
- Gil Blum of Needham issued a Hold rating with the price target of n/a on 1 day ago
- Benjamin Burnett of Stifel Nicolaus issued a Hold rating with the price target of $ 5.3 on 1 day ago
- David Nierengarten of Wedbush issued a Hold rating with the price target of $ 7 on 1 day ago
If you are wondering if FATE is a good stock to buy, here are 3rd party ratings for FATE stock:
- TipRanks.com: Hold
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 22% (56 out of 250)
What is the sentiment on the street regarding Fate Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for FATE stock: Bearish
- Blogger Consensus for FATE stock: Bullish
- Media Buzz for FATE stock: Very High
- Insider Signal for FATE stock: n/a
- Investor Sentiment for FATE stock: Very Negative
- Hedge Fund signal for FATE stock: Positive
The stock market is extremely volatile, and you need to do your own research on FATE stock including scouring the social networks like FATE StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for FATE stock chart >>
Summary: Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
- Recent SNYNF Stock Price: $95.80
- Yearly Gain for SNYNF stock: -1.47%
- Market Cap for SNYNF stock: $122.36B
- P/E Ratio for SNYNF stock: 15.9
Will SNYNF's stock price go up? Is there an accurate SNYNF stock forecast available?
TipRanks.com reports that Sanofi currently has 14 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $111.27. The target pricing ranges from a high SNYNF forecast of $141.04 down to a low forecast of $89.47. Sanofi (SNYNF)’s last closing stock price was $95.80 which would put the average price target at 16.15% upside.
In addition, TradingView issued a Buy rating for SNYNF stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SNYNF stock.
Other analysts covering SNYNF include:
- Dominic Lunn of Credit Suisse issued a Buy rating with the price target of $ 121.57 on 1 day ago
- Peter Welford of Jefferies issued a Buy rating with the price target of $ 127.97 on 2 days ago
- Emmanuel Papadakis of Deutsche Bank issued a Hold rating with the price target of $ 90.64 on 3 days ago
- Eric Le Berrigaud of Stifel Nicolaus issued a Buy rating with the price target of $ 117.3 on 3 days ago
If you are wondering if SNYNF is a good stock to buy, here are 3rd party ratings for SNYNF stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: buy
- Zacks.com: n/a
What is the sentiment on the street regarding Sanofi? (Current ratings compiled by TipRanks.com)
- News Sentiment for SNYNF stock: Very Bullish
- Blogger Consensus for SNYNF stock: n/a
- Media Buzz for SNYNF stock: Low
- Insider Signal for SNYNF stock: n/a
- Investor Sentiment for SNYNF stock: Very Positive
- Hedge Fund signal for SNYNF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on SNYNF stock including scouring the social networks like SNYNF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SNYNF stock chart >>
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
- Recent BIIB Stock Price: $279.25
- Yearly Gain for BIIB stock: 14.45%
- Market Cap for BIIB stock: $40.21B
- P/E Ratio for BIIB stock: 13.837
Will BIIB's stock price go up? Is there an accurate BIIB stock forecast available?
TipRanks.com reports that Biogen currently has 23 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $314.57. The target pricing ranges from a high BIIB forecast of $370.00 down to a low forecast of $247.00. Biogen (BIIB)’s last closing stock price was $279.25 which would put the average price target at 12.65% upside.
In addition, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB stock.
Other analysts covering BIIB include:
- Ami Fadia of Needham issued a Buy rating with the price target of $ 300 on 1 day ago
- Salim Syed of Mizuho Securities issued a Buy rating with the price target of $ 325 on 1 day ago
- Brian Abrahams of RBC Capital issued a Buy rating with the price target of $ 362 on 2 days ago
- Geoff Meacham of Bank of America Securities issued a Hold rating with the price target of $ 295 on 3 days ago
If you are wondering if BIIB is a good stock to buy, here are 3rd party ratings for BIIB stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 22% (56 out of 250)
What is the sentiment on the street regarding Biogen? (Current ratings compiled by TipRanks.com)
- News Sentiment for BIIB stock: Very Bullish
- Blogger Consensus for BIIB stock: Bullish
- Media Buzz for BIIB stock: Very High
- Insider Signal for BIIB stock: n/a
- Investor Sentiment for BIIB stock: Very Negative
- Hedge Fund signal for BIIB stock: Positive
The stock market is extremely volatile, and you need to do your own research on BIIB stock including scouring the social networks like BIIB StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BIIB stock chart >>
Summary: Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience. Exparel, the company's flagship product, is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. The company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications.
- Recent PCRX Stock Price: $37.08
- Yearly Gain for PCRX stock: -38.23%
- Market Cap for PCRX stock: $1.70B
- P/E Ratio for PCRX stock: 93.731
Will PCRX's stock price go up? Is there an accurate PCRX stock forecast available?
TipRanks.com reports that Pacira Pharmaceuticals currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $66.38. The target pricing ranges from a high PCRX forecast of $88.00 down to a low forecast of $50.00. Pacira Pharmaceuticals (PCRX)’s last closing stock price was $37.08 which would put the average price target at 79.02% upside.
In addition, TradingView issued a Sell rating for PCRX stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PCRX stock.
Other analysts covering PCRX include:
- Serge Belanger of Needham issued a Buy rating with the price target of $ 63 on 1 day ago
- Gary Nachman of BMO Capital issued a Hold rating with the price target of $ 52 on 1 day ago
- Unknown Analyst of Truist Financial issued a Buy rating with the price target of $ 68 on 1 day ago
- Gregory Renza of RBC Capital issued a Buy rating with the price target of $ 80 on 2 days ago
If you are wondering if PCRX is a good stock to buy, here are 3rd party ratings for PCRX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 32% (79 out of 250)
What is the sentiment on the street regarding Pacira Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for PCRX stock: Very Bullish
- Blogger Consensus for PCRX stock: Bullish
- Media Buzz for PCRX stock: Very High
- Insider Signal for PCRX stock: n/a
- Investor Sentiment for PCRX stock: Very Positive
- Hedge Fund signal for PCRX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on PCRX stock including scouring the social networks like PCRX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PCRX stock chart >>
Summary: Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
- Recent ZBH Stock Price: $125.70
- Yearly Gain for ZBH stock: 1.95%
- Market Cap for ZBH stock: $26.38B
- P/E Ratio for ZBH stock: 95.313
Will ZBH's stock price go up? Is there an accurate ZBH stock forecast available?
TipRanks.com reports that Zimmer Biomet Holdings currently has 15 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $127.38. The target pricing ranges from a high ZBH forecast of $145.00 down to a low forecast of $95.00. Zimmer Biomet Holdings (ZBH)’s last closing stock price was $125.70 which would put the average price target at 1.34% upside.
In addition, TradingView issued a Neutral rating for ZBH stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ZBH stock.
Other analysts covering ZBH include:
- Jayson Bedford of Raymond James issued a Buy rating with the price target of $ 144 on 2 days ago
- Matthew O'Brien of Piper Sandler issued a Hold rating with the price target of $ 130 on 2 days ago
- Vijay Kumar of Evercore ISI issued a Hold rating with the price target of $ 130 on 4 days ago
If you are wondering if ZBH is a good stock to buy, here are 3rd party ratings for ZBH stock:
- TipRanks.com: Hold
- TradingView.com: Neutral
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 36% (161 out of 250)
What is the sentiment on the street regarding Zimmer Biomet Holdings? (Current ratings compiled by TipRanks.com)
- News Sentiment for ZBH stock: Very Bullish
- Blogger Consensus for ZBH stock: Bullish
- Media Buzz for ZBH stock: Medium
- Insider Signal for ZBH stock: n/a
- Investor Sentiment for ZBH stock: Very Negative
- Hedge Fund signal for ZBH stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ZBH stock including scouring the social networks like ZBH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ZBH stock chart >>
Summary: atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
- Recent ATAI Stock Price: $1.82
- Yearly Gain for ATAI stock: -71.65%
- Market Cap for ATAI stock: $301.89M
- P/E Ratio for ATAI stock: -1.458
Will ATAI's stock price go up? Is there an accurate ATAI stock forecast available?
TipRanks.com reports that ATAI Life Sciences currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.50. The target pricing ranges from a high ATAI forecast of $50.00 down to a low forecast of $15.00. ATAI Life Sciences (ATAI)’s last closing stock price was $1.82 which would put the average price target at 1246.15% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ATAI stock.
Other analysts covering ATAI include:
- Caroline Palomeque of Berenberg Bank issued a Buy rating with the price target of $ 18 on 1 day ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $ 50 on 1 day ago
- Sumant Kulkarni of Canaccord Genuity issued a Buy rating with the price target of $ 27 on 1 month ago
If you are wondering if ATAI is a good stock to buy, here are 3rd party ratings for ATAI stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 6% (235 out of 250)
What is the sentiment on the street regarding ATAI Life Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for ATAI stock: Neutral
- Blogger Consensus for ATAI stock: Bullish
- Media Buzz for ATAI stock: High
- Insider Signal for ATAI stock: n/a
- Investor Sentiment for ATAI stock: Very Negative
- Hedge Fund signal for ATAI stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ATAI stock including scouring the social networks like ATAI StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ATAI stock chart >>
Summary: Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA.
- Recent IPSC Stock Price: $4.92
- Yearly Gain for IPSC stock: -62.78%
- Market Cap for IPSC stock: $290.15M
- P/E Ratio for IPSC stock: -2.196
Will IPSC's stock price go up? Is there an accurate IPSC stock forecast available?
TipRanks.com reports that Century Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.86. The target pricing ranges from a high IPSC forecast of $28.00 down to a low forecast of $14.00. Century Therapeutics (IPSC)’s last closing stock price was $4.92 which would put the average price target at 263.01% upside.
In addition, TradingView issued a Sell rating for IPSC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on IPSC stock.
Other analysts covering IPSC include:
- Mitchell Kapoor of H.C. Wainwright issued a Buy rating with the price target of $ 19 on 1 day ago
- Daina Graybosch of SVB Securities issued a Buy rating with the price target of $ 14 on 1 day ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $ 14 on 2 days ago
- Unknown Analyst of EF Hutton issued a Buy rating with the price target of $ 16 on 3 days ago
If you are wondering if IPSC is a good stock to buy, here are 3rd party ratings for IPSC stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 32% (79 out of 250)
What is the sentiment on the street regarding Century Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for IPSC stock: Very Bullish
- Blogger Consensus for IPSC stock: n/a
- Media Buzz for IPSC stock: Very High
- Insider Signal for IPSC stock: n/a
- Investor Sentiment for IPSC stock: n/a
- Hedge Fund signal for IPSC stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on IPSC stock including scouring the social networks like IPSC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IPSC stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================